{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:42:00Z","timestamp":1783132920783,"version":"3.54.6"},"reference-count":27,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2014,3,12]],"date-time":"2014-03-12T00:00:00Z","timestamp":1394582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2014,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>The efficacy and safety of canagliflozin, a sodium glucose co\u2010transporter 2 inhibitor, was evaluated in patients with type 2 diabetes mellitus (<jats:styled-content style=\"fixed-case\">T2DM<\/jats:styled-content>) inadequately controlled with metformin and pioglitazone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this randomized, double\u2010blind, phase 3 study, patients (N\u2009=\u2009342) received canagliflozin 100 or 300\u2009mg during a 26\u2010week, placebo\u2010controlled, core period and a 26\u2010week, active\u2010controlled extension in which placebo\u2010treated patients were switched to sitagliptin 100\u2009mg. Efficacy comparisons for canagliflozin versus placebo at week 26 are reported, with no comparisons versus sitagliptin at week 52 (sitagliptin used to maintain double\u2010blind and control for safety). Safety data are reported for canagliflozin and placebo\/sitagliptin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Canagliflozin 100 and 300\u2009mg significantly lowered haemoglobin A1c (<jats:styled-content style=\"fixed-case\">HbA1c<\/jats:styled-content>) compared with placebo at week 26 (\u22120.89%, \u22121.03% and \u22120.26%; p &lt; 0.001); reductions with canagliflozin 100 and 300\u2009mg were maintained at week 52 (\u22120.92% and \u22121.03%). Relative to placebo, both canagliflozin doses significantly reduced body weight (\u22122.5 and \u22123.5\u2009kg), fasting plasma glucose and systolic blood pressure (<jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content>) at week 26 (p &lt; 0.05 for all), with reductions maintained at week 52. Overall adverse event (<jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>) incidence over 52 weeks was 69.9, 76.3 and 76.5% with canagliflozin 100 and 300\u2009mg and placebo\/sitagliptin; <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>\u2010related discontinuation and serious <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content> rates were low. Incidences of genital mycotic infections and <jats:styled-content style=\"fixed-case\">AEs<\/jats:styled-content> related to osmotic diuresis and volume depletion were higher with canagliflozin than placebo\/sitagliptin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Canagliflozin improved glycaemic control, reduced body weight and systolic <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content>, and was generally well tolerated in patients with <jats:styled-content style=\"fixed-case\">T2DM<\/jats:styled-content> on metformin and pioglitazone over 52 weeks.<\/jats:p><\/jats:sec>","DOI":"10.1111\/dom.12273","type":"journal-article","created":{"date-parts":[[2014,2,17]],"date-time":"2014-02-17T06:16:41Z","timestamp":1392617801000},"page":"467-477","source":"Crossref","is-referenced-by-count":217,"title":["Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone"],"prefix":"10.1111","volume":"16","author":[{"given":"T.","family":"Forst","sequence":"first","affiliation":[{"name":"Profil Mainz Mainz Germany"},{"name":"Johannes Gutenberg University Mainz Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Guthrie","sequence":"additional","affiliation":[{"name":"The Ohio State University Columbus OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Goldenberg","sequence":"additional","affiliation":[{"name":"LMC Diabetes &amp; Endocrinology Thornhill Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Yee","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Vijapurkar","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Meininger","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Stein","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,3,12]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-S011"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0413"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1926"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12054"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2491"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12090"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.3810\/hp.2013.04.1020"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60683-2"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-3039-1"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12322"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01558.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01406.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-4205"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2008.01023.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2009.01055.x"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2009.02857.x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60590-9"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1693"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12188"},{"issue":"1","key":"e_1_2_7_21_1","first-page":"S313","article-title":"Canagliflozin, a sodium glucose co\u2010transporter 2 inhibitor, reduces body weight mainly through loss of fat mass in subjects with type 2 diabetes (Abstract 762)","volume":"55","author":"Toubro S","year":"2012","journal-title":"Diabetologia"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2013.05.007"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.86.9.4047"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.2174\/156652412802480970"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2013.04.003"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01291.x"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12269"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.2337\/db10-1328"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12273","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.12273","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.12273","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T08:02:39Z","timestamp":1760342559000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,12]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["10.1111\/dom.12273"],"URL":"https:\/\/doi.org\/10.1111\/dom.12273","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,12]]}}}